

Advanced Bio Tech



Rapid Therapeutic Science Laboratories

BUILDING THE WORLD'S BEST CANNABIS DELIVERY DEVICES!

Safe. Reliable. Effective. Fast-Acting.

SAFE HARBOR STATEMENT

Statements in this presentation regarding Rapid Therapeutic Science Laboratories, Inc. (RTSL) that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. It is routine for our internal projections and expectations to change. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the projections or forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory or licensing approvals, technology systems beyond our control; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties, changes in state laws or regulations regarding legal cannabis operations, and potential escalation of federal enforcement of cannabis prohibition. Readers are referred to filings of RTSL with the Securities and Exchange Commission and other reports and documents that will be filed from time to time by us, which will be made available online at www.sec.gov. This presentation is qualified in its entirety by the information contained in the Private Offering Memorandum (POM) and no reliance should be placed on the accuracy or completeness of the information contained in this presentation. In making an investment decision, investors should rely solely on the information contained in the POM and other securities documents the Company has provided them. Neither the Company nor the placement agent, if any, or any of their respective affiliates, advisors or representatives shall bear any liability whatsoever (in negligence or otherwise) for any loss arising from any use of this presentation.

NINE REASONS TO INVEST IN TODAY!

- Industry leader in MDI formulation and manufacturing in CBD & legal Cannabis space
- Super pure formulation process with 98% bioavailability - well positioned to replace vape pens, edibles & tinctures
- Annual run-rate approaching \$2.5M – and should ramp up rapidly with introduction of our new **nhāler** brand, a consumer-focused product line
- **Rxoid™** product line has been on the market since early 2020 – and is enjoying wide-spread acceptance in the medical practitioner and pharmaceutical sectors
- Product being successfully tested by NFL, MLB and collegiate athletes
- Clean balance sheet – zero long term debt after completion of next \$250,000 in funding.
- Management has 150+ years of successful private/public company experience plus Cannabis domain and capital markets expertise
- Tightly controlled cap structure; TMDI holds over 85% of outstanding shares
- RTSL expects a **NASDAQ** up-listing within the next fiscal year **and/or** an acquisition by a major health company within 24 months – either exit event could provided significant upside for selling shareholders; the **private placement common shares** acquired in this or subsequent offerings would be **freely tradable in six months under Rule 144**

RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.

(OTC:RTSL)


Who We Are and What We Do

- **Big Pharma Trained Professionals**, pursuant to cGMP, to manufacture Metered Dose Inhalers (“MDIs”) using CBD, CBG, CBN, THCva and Terpenes, Prescription Medications and GRAES Drugs:
 - Branded product available from medical practitioners and pharmacies: **Rxoid™**
 - Contract Production: white label and private label
- **Formulate Cannabinoid Blends** for human inhalation via aerosol delivery directly to the blood stream (systemic) through the pulmonary system (lungs).
We have developed **10 Proprietary Formulas** to date and more on the drawing board.
- **Formulate Innovative Natural and Lab Created Products** for delivery through the pulmonary system. This includes new emerging drugs such as psilocybin and exomes.
- **Sell FDA approved** filling equipment, consumables (cans, valves and actuators) and propellant listed in FDA Drug Master Files (DMF).
- **Consult with Strategic Partners** in the cannabis space (THC) via joint ventures and royalty driven products in legal jurisdictions including, but not limited to, CA, NV, OK, and FL.

How to Deliver Drugs to the Lungs?

- Aerosol Delivery System – Metered Dose Inhaler (“MDI”)
- An Aerosol Delivery System is a device that takes a bulk liquid formulation and disperses it into aerosol droplets appropriate for inhalation.

Figure 33-10 Gas exchange between alveoli and capillaries



RTSL's MDIs Give Better, Faster Relief

- RTSL's Metered Dose Inhalers (MDIs) deliver accurate, safe, fast acting, highly bioavailable, cost effective relief compared to leading cannabinoid delivery systems (*e.g. ingestible or topical routes of administration*)



➤ Accurate Dosing

- Cannabinoid gummies, oils, creams, etc. can not guarantee the same dose every time.



➤ Trust in Quality Ingredients

- RTSL only uses pharmaceutical grade Cannabinoids (tested at 99.9% pure).



➤ Fast Acting

- RTSL 's MDIs delivers cannabinoids almost instantly into the blood stream



➤ Bioavailability and Value

- RTSL 's MDIs are 98% bioavailable... making it the most cost effective route of administration.

The Value Equation – Consumer Education is Critical

OURS



THEIRS



➤ Cannabinoids costs approximately \$0.30 per mg in the blood stream at retail pricing through RTSL's MDI

- Significantly more cost effective than vape pens which deliver CBD to the blood stream for an average of about \$1.25 per mg or ingestible CBD products averaging around \$0.80 per mg.

➤ Understanding 98% Bioavailability is Key...!

- 98% of each dose of cannabinoid is delivered to the deep lung tissue for immediate transport to your brain via your systemic blood stream.
- Only 2% is lost during exhalation.
- A properly formulated and designed MDI is **200%** more efficient in delivery of cannabinoids to the blood stream compared to smoking or vaping.
- Compared to an edible, a RTSL MDI is up to **2000%** more efficient in delivering CBD into the blood stream.

Quality Ingredients – Designed for the Medical Community

- RTSL MDIs only use 99.9% pure pharmaceutical grade cannabinoids.
- RTSL MDIs do not use “full spectrum oil” so consumers don’t have to worry about the dangers or side effects of:
 - Wax, tar, toxins
 - Fillers or lipids (oils)
 - Sugars
 - Undesirable terpenes that may be harmful
 - Colorings and/or other contaminants such as heavy metals and carcinogenic byproducts
 - Chlorophyll
 - Vitamin E
 - PG or PEG
- RTSL’s competitors generally use “full spectrum oil” and illegal excipients including, but not limited to compressed air, which can produce a dangerous, bad tasting product.




Safety – the FDA and Beyond

- RTSL filling equipment, cans, valves and actuators are FDA approved and listed in Drug Master Files.
- We are registering RTSL's MDI lineup of formulations with the FDA, step one in FDA approval (Deemed Rules).
- The only ingredients in RTSL's MDI that are not regulated and approved by the FDA are the cannabinoids themselves. We only use pure isolates.
- CBD, if it is pure cannabidiol, can be safely inhaled in the lungs; just like it can be consumed in an IV.
- All other ingredients in RTSL's MDI are approved for inhalation by the FDA:
 - ETOH
 - HFA-134a
 - Certain Terpenes, if any
 - H₂O, if any
- No oil, food grade or otherwise, is approved or allowed to be inhaled in humans which can cause lipoid pneumonia; ergo no “full spectrum oil”. RTSL has its own “entourage” blends of terpenes approved for inhalation.
- No essential oils can be inhaled.
- Compressed air cannot be used in an MDI. (Physics apply to medical devices and the human body's physiology).
- Improperly prepared MDIs are very dangerous, and possibly life threatening.

Accurate Dosing – No Fire, No Heat

- MDI have been safely and conveniently used for almost 70 years world-wide to treat pulmonary disease (COPD).
- When the MDI is properly formulated and correctly used, all you must do is inhale (actuate). Upon actuation you consume either a 2.5 or a 5 mg dose of a cannabinoid or a blend of multiple cannabinoids depending on size of the MDI. Each dose is 98% bioavailable. (A 10mg MDI is being tested on professional athletes).
- Note: We buy our cGMP compliant equipment and critical parts from Coster MDI, SA the largest aerosol parts manufacturer in the world.
- Coster MDI, SA has provided us with over \$1,000,000 in consumables on consignment above our current owned inventory in anticipation of pending orders. Another \$3,000,000 in consumables is being prepared for shipment along with additional automatic filling machines.

Fast Acting and Additional Benefits



- When consumed correctly, a RTSL MDI will deliver an exact metered dose of cannabinoids into your lungs for immediate adsorption into your bloodstream... then straight to your brain.
- The RTSL MDI
 - Provides a precise and accurate dose
 - Requires no heat or fire
 - Contains multiple doses
 - Is inexpensive
 - Is easy to use
 - Is portable and fits in your pocket or purse
 - Is tamper proof
 - Requires no charging or batteries
 - Is waterproof

Additional Cannabinoid Formulas

Product Line Extensions

- **CBD and CBG:** Supports enhanced pain control, inflammation and anxiety.
- **CBG:** Supports pain management without entourage effects.
- **CBD and CBN:** Supports sleep.
- **CBT and/or THCva (non-hallucinogenic):** Supports weight loss.
- **Product Line Extensions for Entourage Effects:**
 - Relief
 - Movement
 - Allergy
 - Rest
 - Relax
 - Alert
 - Open Air

Aerosol Formulas Being Tested

- Virus suppression in mouth, nose, lungs and on mask.
- Potential replacement for Adderall.
- Psilocybin.

Management Team & Advisors

Donal R. Schmidt, Jr. (59) – CEO/COB – Prior to Rxoid™, president of several public companies; Licensed attorney, CPA, MBA Finance, University of Texas, Degrees in Math and Chemistry.

Sean Berrier (48) – Senior VP – 30 years of diversified experience in the hemp and cannabis space; owned and operated hemp and cannabis farms in Oregon for 5 years.

Hughes Watler (70) – CFO/Board Member – CPA with 25+ years of senior management experience; CFO of NSYE company with \$1Billion market cap; MBA, University of Texas.

Ryan Southern (40) – VP of Marketing and Client Relations – 18 years pharmaceutical marketing experience with major prescription and GRAES product lines such as Mucinex.

Robert (Rob) Renick (59) – VP of Sales – 25+ years of senior management experience with large MLM and Affiliate Marketing Groups in both national and international territories.

Richard (Rick) Adams, Ph.D. (50) – Chief Technical Science Officer - Stanford University trained anesthesiologist with Ph.D. in Organic Chemistry.

Current Capital Structure

Equity

140,000,000	Common restricted shares - Controlling Shareholder
<u>16,856,000</u>	Common unrestricted shares – Approximately 6 founders
156,856,000	Total Outstanding Shares

Convertible Debt

- \$1,121,775 owed to 2 founders converts to approximately 20,000,000 restricted shares over 5 years.

Current Raise – up to \$4,000,000 (16,000,000 common shares at \$0.25/share)

- **\$630,000 Marketing:** Digital ads, media buys
- **\$370,000 Brand Development:** Digital Channeling, Geo-fencing, travel, brand awareness.
- **\$200,000 FDA/Lab:** ISO 5/13485 Lab certification, additional filling machines.
- **\$800,000 inventory:** Pre-order additional consumables and API.
- **\$797,000 G&A:** if needed.

NINE REASONS TO INVEST IN TODAY!

- Industry leader in MDI formulation and manufacturing in CBD & legal Cannabis space
- Super pure formulation process with 98% bioavailability - well positioned to replace vape pens, edibles & tinctures
- Annual run-rate approaching \$2.5M – and should ramp up rapidly with introduction of our new **nhāler** brand, a consumer-focused product line
- **Rxoid™** product line has been on the market since early 2020 – and is enjoying wide-spread acceptance in the medical practitioner and pharmaceutical sectors
- Product being successfully tested by NFL, MLB and collegiate athletes
- Clean balance sheet – zero long term debt after completion of next \$250,000 in funding.
- Management has 150+ years of successful private/public company experience plus Cannabis domain and capital markets expertise
- Tightly controlled cap structure; TMDI holds over 85% of outstanding shares
- RTSL expects a **NASDAQ** up-listing within the next fiscal year **and/or** an acquisition by a major health company within 24 months – either exit event could provided significant upside for selling shareholders; the **private placement common shares** acquired in this or subsequent offerings would be **freely tradable in six months under Rule 144**



5580 Peterson Lane, Suite 200 Dallas, TX 75240

Phone: 800-497-6059 Fax: 877-676-8527

Email: info@rtslco.com

Corporate Website: www.rtslco.com

Branded Website: www.rxoid.com

Contact: Don Schmidt, CEO

BUILDING THE WORLD'S BEST CANNABIS DELIVERY DEVICES!

Safe. Reliable. Effective. Fast-Acting.